Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Spago Nanomedical AB (publ)
  6. Summary
    SPAG   SE0004899474

SPAGO NANOMEDICAL AB (PUBL)

(SPAG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
11/24/2021 11/25/2021 11/26/2021 11/29/2021 11/30/2021 Date
4.995(c) 4.935(c) 4.75(c) 4.465(c) 4.42(c) Last
79 014 4 707 58 397 82 819 45 160 Volume
-3.38% -1.20% -3.75% -6.00% -1.01% Change
More quotes
Estimated financial data (e)
Sales 2021 0,70 M 0,08 M 0,08 M
Net income 2021 -42,1 M -4,67 M -4,67 M
Net Debt 2021 - - -
P/E ratio 2021 -4,33x
Yield 2021 -
Sales 2022 69,9 M 7,75 M 7,75 M
Net income 2022 19,8 M 2,20 M 2,20 M
Net Debt 2022 - - -
P/E ratio 2022 9,21x
Yield 2022 -
Capitalization 182 M 20,1 M 20,2 M
Capi. / Sales 2021 260x
Capi. / Sales 2022 2,60x
Nbr of Employees 17
Free-Float 100%
More Financials
Company
Spago Nanomedical publ AB, formerly Spago Imaging publ AB, is a Sweden-based biotechnology company. It specialized in the areas of contrast agents and nanoscale life science research. The Company is involved in three projects: Spago Pix, a nanomaterial developed for use as a cancer selective contrast agent for Magnetic Resonance Imaging (MRI); the therapeutic project Tumorad, using nanoparticles loaded with... 
More about the company
Ratings of Spago Nanomedical AB (publ)
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SPAGO NANOMEDICAL AB (PUBL)
11/10Spago Nanomedical interim report January-September 2021
AQ
11/10Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months End..
CI
11/10Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®
AQ
11/10Spago Nanomedical Selects Cmed Group Limited as its CRO for the First Clinical Trial wi..
CI
10/21SPAGO NANOMEDICAL : Nomination committee appointed for the 2022 Annual General Meeting in ..
AQ
10/12BIOSTOCK : Spago Nanomedical's CDO is in place
AQ
08/24SPAGO NANOMEDICAL : interim report January-June 2021
AQ
08/24Spago Nanomedical AB Reports Earnings Results for the Second Quarter and Six Months End..
CI
08/03SPAGO NANOMEDICAL : appoints Paul Hargreaves as Chief Development Officer
AQ
08/03Spago Nanomedical AB Appoints Paul Hargreaves as Chief Development Officer
CI
06/21BIOSTOCK :  Spago Nanomedical's CEO about the plans for the coming twelve months
AQ
05/05SPAGO NANOMEDICAL : Bulletin from the 2021 Annual General Meeting of Spago Nanomedical AB ..
AQ
04/28SPAGO NANOMEDICAL : interim report January-March 2021
AQ
04/28Spago Nanomedical AB Reports Earnings Results for the Quarter Ended March 31, 2021
CI
02/02Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31,..
CI
More news
News in other languages on SPAGO NANOMEDICAL AB (PUBL)

- No features available -

More news
Chart SPAGO NANOMEDICAL AB (PUBL)
Duration : Period :
Spago Nanomedical AB (publ) Technical Analysis Chart | SPAG | SE0004899474 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 4,42 SEK
Average target price 11,50 SEK
Spread / Average Target 160%
EPS Revisions
Managers and Directors
Mats Hansen Chief Executive Officer
Hanna Olsson Chief Financial Officer
Eugen Steiner Chairman
Oskar Axelsson Chief Scientific Officer & Vice President
Peter Leander Independent Director
Sector and Competitors